Note: Ingredients listed on restricted chemical lists
EC/CAS
231-791-2/7732-18-5
Name of the chemical
Water, distilled, conductivity or of similar purity H2O
Concentration
90-99
EC/CAS
247-852-1/26628-22-8
Name of the chemical
Sodium Azide
Concentration
<0,1
General Information
Version
D.6
Revision date
2022-05-02
Product name
VitalScreen Reagent 1
1.2.1 Relevant identified uses
Industrial/Professional use spec
Emergency telephone
+3250791805
Icons in SDS
Company Information
company name
FertiPro NV
e-mail address of the competent person responsible for the Safety Data Sheet
info@fertipro.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H317
Hazard statements
Code
Statements
H317
May cause an allergic skin reaction
Section 2
SECTION 2: Hazards identification
According to Regulation (EC) No. 1272/2008 (CLP)]
2.1 Classification of the substance or mixture
Classification
Hazard statements
see section 16 : H317 - May cause an allergic skin reaction.
Adverse physicochemical, human health and environmental effects
No additional information available
2.2 Label elements
Labelling
Hazard pictograms
GHS07
Signal word
Warning
Hazardous Ingredients
Eosin
Precautionary statements
P261 - Avoid breathing dust/fume/gas/mist/vapours/ spray. P272 - Contaminated work clothing should not be allowed out of the workplace. P280 - Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/… P302+P352 - IF ON SKIN: Wash with plenty of water/… P321 - Specific treatment (see supplemental first aid instruction on this label). P333+P313 - If skin irritation or rash occurs: get medical advice/attention. P362+P364 - Take off contaminated clothing and wash it before reuse. P501 - Dispose of contents/container to …
2.3 Other hazards
Contains no PBT/vPvB substances ≥ 0.1% assessed in accordance with REACH Annex XIII. The mixture does not contain substance(s) included in the list established in accordance with Article 59(1) of REACH for having endocrine disrupting properties, or is not identified as having endocrine disrupting properties in accordance with the criteria set out in Commission Delegated Regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605.
